Addex Therapeutics Ltd is a biopharmaceutical company focused on the development of novel, orally available small molecule drugs to treat diseases of the central nervous system. The company’s lead product candidate, dipraglurant, is currently in clinical trials for the treatment of Parkinson’s disease and levodopa-induced dyskinesia.
